

# Timor-Leste

Population 2016

1.3 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.3 (0.75–1.9)	100 (59–150)
Mortality (HIV+TB only)	<0.01 (0–0.035)	0.29 (0–2.7)
Incidence (includes HIV+TB)	6.3 (4.1–9)	498 (322–712)
Incidence (HIV+TB only)	0.059 (0.038–0.084)	4.6 (3–6.6)
Incidence (MDR/RR-TB)**	0.21 (0.13–0.28)	16 (10–22)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.37 (0.22–0.51)	2.2 (1.3–3)	2.6 (1.6–3.6)
Males	0.42 (0.25–0.58)	3.3 (2–4.7)	3.8 (2.3–5.2)
Total	0.79 (0.48–1.1)	5.5 (3.4–7.7)	6.3 (4.1–9)

TB case notifications, 2016	
Total cases notified	3 620
Total new and relapse	3 607
- % tested with rapid diagnostics at time of diagnosis	0%
- % with known HIV status	45%
- % pulmonary	85%
- % bacteriologically confirmed among pulmonary	61%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	57% (40–88)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.21 (0.1–0.34)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	23	1%
- on antiretroviral therapy	23	100%

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			100 (88–110)
Estimated % of TB cases with MDR/RR-TB	2.8% (2.4–3.1)	13% (10–15)	
% notified tested for rifampicin resistance	37%	96%	1 421
MDR/RR-TB cases tested for resistance to second-line drugs			6
Laboratory-confirmed cases		MDR/RR-TB: 6, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 6, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	87%	1 650
Previously treated cases, excluding relapse, registered in 2015	75%	12
HIV-positive TB cases registered in 2015	68%	19
MDR/RR-TB cases started on second-line treatment in 2014	100%	3
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (93–100)

TB financing, 2017	
National TB budget (US\$ millions)	1.9
Funding source: 11% domestic, 89% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically